Barely Significant
← all excerpts

Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions.

Pharmaceuticals (Basel) · 2025 · PMC11944903 · PMID 40143208

1
hedged sentence
closest p
boldest claim

The sentences

Interestingly, a sub-analysis of the trial [ 22 ] using the universal definition of MI, compared to the original definition used by the steering committee, showed reduced rates of the primary endpoint in both arms, which, however, still did not reach statistical significance (cangrelor 4.9% vs. placebo 6.0%; OR: 0.80; 95%CI: 0.63–1.02).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.